Resources from the same session
LBA23 - Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361
Presenter: Ajjai Alva
Session: Proffered Paper - GU, non prostate 1
Resources:
Abstract
Slides
Webcast
697O - A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE)
Presenter: Thomas Powles
Session: Proffered Paper - GU, non prostate 1
Resources:
Abstract
Slides
Webcast
LBA24 - TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI)
Presenter: Yohann Loriot
Session: Proffered Paper - GU, non prostate 1
Resources:
Abstract
Slides
Webcast
698O - Patient-reported outcomes (PROs) from IMvigor130: A global, randomised, partially blinded phase III study of atezolizumab (atezo) + platinum-based chemotherapy (PBC) vs placebo (PBO) + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Aristotelis Bamias
Session: Proffered Paper - GU, non prostate 1
Resources:
Abstract
Slides
Webcast
699O - Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): Association between clinical outcomes and exploratory biomarkers
Presenter: Srikala Sridhar
Session: Proffered Paper - GU, non prostate 1
Resources:
Abstract
Slides
Webcast
Q&A and live discussion
Presenter: Richard Cathomas
Session: Proffered Paper - GU, non prostate 1
Resources:
Webcast
Invited Discussant LBA24, 698O and 699O
Presenter: Jürgen Gschwend
Session: Proffered Paper - GU, non prostate 1
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Richard Cathomas
Session: Proffered Paper - GU, non prostate 1
Resources:
Webcast